Bletilla striata polysaccharide‑zinc complex ameliorates ulcerative colitis by modulating endoplasmic reticulum stress-associated autophagy and apoptosis.

What To Know

This paper reports preclinical laboratory and mouse-model experiments of a Bletilla striata polysaccharide–zinc complex (BSP‑Zn) tested as a potential treatment for ulcerative colitis. In mice given DSS to induce colitis, BSP‑Zn at two doses reduced colonic tissue damage and lowered pro‑inflammatory cytokine production compared with controls.

In cultured HCT116 cells treated with thapsigargin to induce endoplasmic reticulum stress (ERS), the authors report that BSP‑Zn reduced activation of ERS pathways and downstream autophagy and apoptosis signals.

The study is mechanistic and preclinical: it combines in vivo (mouse) and in vitro (cell line) experiments to explore how BSP‑Zn might work, focusing on ER stress–related pathways rather than reporting human safety or efficacy.

The authors conclude the findings provide a rationale for further translational investigation of BSP‑Zn as a candidate therapy for UC. This is not clinical evidence and does not mean BSP‑Zn is safe or effective for people with UC.

It is an early-stage, hypothesis‑generating set of experiments that may guide additional preclinical work or eventual clinical trials.